Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications.
Ali Reza SimaBahar Saberzadeh-ArdestaniHomayoon VahediHafez FakheriFariborz Mansour-GhanaeiIradj MalekiSiavosh Nasseri-MoghaddamHasan VosoghiniaMohammad Reza GhadirAhmad HormatiAmir KasaeianAmir Reza RadmardBardia KhosraviMasoud MalekzadehSudabeh AlatabAnahita SadeghiNayyereh AminisaniHossein PoustchiElnaz GonoudiAmir AnushiravaniMaryam RayatpishehJean-Frederic ColombelRyan C UngaroFatemeh MalekzadehPublished in: Archives of Iranian medicine (2022)
Age, presence of new gastrointestinal symptoms and use of 5-ASA were associated with increased hospitalization rate among IBD patients, while anti-TNF therapy had no statistical association.
Keyphrases
- patients with inflammatory bowel disease
- end stage renal disease
- coronavirus disease
- sars cov
- ejection fraction
- chronic kidney disease
- newly diagnosed
- rheumatoid arthritis
- peritoneal dialysis
- prognostic factors
- type diabetes
- adipose tissue
- mesenchymal stem cells
- insulin resistance
- sleep quality
- physical activity
- skeletal muscle
- patient reported
- glycemic control